(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.24%) $83.77
(-2.26%) $1.601
(0.09%) $2 344.70
(0.41%) $27.47
(0.78%) $927.70
(-0.26%) $0.932
(-0.24%) $10.96
(-0.39%) $0.799
(-0.16%) $92.17
Quarter results today
(tns 2024-04-25)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics...
Stats | |
---|---|
Today's Volume | 15 041.00 |
Average Volume | 110 432 |
Market Cap | 3.76M |
EPS | $0 ( 2024-04-03 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00400 (10.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Scott John K Jr. | Buy | 64 289 | Series J Convertible Preffered Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 270 | Series G Redeemable Preferred Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 400 | Series I Convertible Preferred Stock |
2023-11-16 | Moss Dana J | Buy | 416 667 | Common Stock |
2023-11-16 | Moss Dana J | Buy | 200 000 | Common Stock |
INSIDER POWER |
---|
99.84 |
Last 95 transactions |
Buy: 26 134 406 | Sell: 71 109 |
Navidea Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Navidea Financials
Annual | 2022 |
Revenue: | $65 652.00 |
Gross Profit: | $-119 295 (-181.71 %) |
EPS: | $-0.590 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.0227 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $0.120 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.0243 |
Financial Reports:
No articles found.
Navidea
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators